Home › Funds › DAFNA Capital Management LLC › NGNE
DAFNA Capital Management LLC position in NGNE
NEUROGENE INC · Health Care
DAFNA Capital Management LLC reported holding 150,532 shares of NGNE (NEUROGENE INC) in its Q3 2026 13F filing — a position valued at US$4.2M, representing 0.89% of its reported portfolio and ranking #25 among its reported holdings. DAFNA Capital Management LLC has disclosed NGNE holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How DAFNA Capital Management LLC's NGNE position evolved
DAFNA Capital Management LLC first disclosed a stake in NGNE in Q2 2024 at 11,000 shares (US$400K). The position peaked in Q3 2026 at 150,532 shares, worth US$4.2M. Across 10 filings, DAFNA Capital Management LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 150,532 shares valued at US$4.2M — an increase of 61,500 shares quarter over quarter.. Notable position changes include a 562% increase in Q4 2024 (shares fell 49% over the following quarter), a 102% increase in Q1 2026 (shares rose 56% over the following quarter), a 69% increase in Q3 2026 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 11.00K | $400.29K | New |
| Q3 2024 | 7.78K | $326.24K | Reduce |
| Q4 2024 | 51.50K | $1.18M | Add |
| Q1 2025 | 51.50K | $603.07K | Hold |
| Q2 2025 | 51.10K | $763.88K | Reduce |
| Q3 2025 | 30.38K | $526.40K | Reduce |
| Q4 2025 | 27.97K | $576.26K | Reduce |
| Q1 2026 | 56.63K | $1.14M | Add |
| Q2 2026 | 89.03K | $2.80M | Add |
| Q3 2026 | 150.53K | $4.19M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC) is a Health Care company. 41 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$51.9M), Casdin Capital (US$44.1M), Redmile Group, LLC (US$43.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.87M sh · $51.94M · Q3 2026
- Casdin Capital 1.59M sh · $44.10M · Q3 2026
- Redmile Group, LLC 1.56M sh · $43.46M · Q3 2026
- RTW INVESTMENTS, LP 1.51M sh · $42.08M · Q3 2026
- EcoR1 Capital, LLC 1.27M sh · $35.37M · Q3 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $27.59M · Q3 2026
- Trails Edge Capital Partners, LP 964.88K sh · $26.84M · Q3 2026
- MPM BioImpact LLC 771.84K sh · $21.47M · Q3 2026
- Tyro Capital Management LLC 304.40K sh · $8.47M · Q3 2026
- GREAT POINT PARTNERS LLC 300.00K sh · $8.35M · Q3 2026
- Jones Hill Capital LP 217.70K sh · $6.06M · Q3 2026
More on DAFNA Capital Management LLC
FAQ
How long has DAFNA Capital Management LLC held NGNE?
DAFNA Capital Management LLC has disclosed NGNE holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is DAFNA Capital Management LLC's current position in NGNE?
As of Q3 2026, DAFNA Capital Management LLC holds 150.53K shares of NGNE (NEUROGENE INC), valued at $4.19M, representing 0.89% of its reported portfolio and ranking #25.
Has DAFNA Capital Management LLC been buying or selling NGNE?
In the latest 13F filing (Q3 2026), DAFNA Capital Management LLC increased its position in NGNE. The position peaked in Q3 2026 at 150.53K shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.